S. Busfield

D. Chappell, S. Busfield, S. Klinken, 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

A neutralizing anti–G‐CSFR antibody blocks G‐CSF–induced neutrophilia without inducing neutropenia in nonhuman primates

S. Busfield, H. Huynh, M. Hardy, 2017, Journal of leukocyte biology.

Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.

M. Dottore, Angel F. Lopez, T. Nero, 2014, Cell reports.

Emergence of myeloid cells from cultures of J2E erythroid cells is linked with karyotypic abnormalities.

C. Begley, S. Busfield, S. Klinken, 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells

Angel F. Lopez, H. Ramshaw, A. Roberts, 2012 .

Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation.

Michael J. Wilson, S. Dower, S. Busfield, 2018, The Journal of allergy and clinical immunology.

First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse

A. Roberts, B. Smith, S. Busfield, 2014 .

A new nomenclature for IL-1-family genes.

J. E. Ford, R. Kastelein, P. Young, 2001, Trends in immunology.

Identification and gene organization of three novel members of the IL-1 family on human chromosome 2.

S. Busfield, J. Smutko, D. Gearing, 2000, Genomics.

Generation and Characterization of Neuregulin-2-Deficient Mice

J. Britto, S. Busfield, P. Hertzog, 2004, Molecular and Cellular Biology.

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.

J. Dick, Angel F. Lopez, H. Ramshaw, 2009, Cell stem cell.

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

E. Nievergall, J. Reynolds, W. Erber, 2016, Leukemia.

Development and Characterization of an Anti-FXIIa Monoclonal Antibody for the Treatment of Hereditary Angioedema

Michael J. Wilson, S. Busfield, M. Hardy, 2015 .

Regulation of the erythropoietin receptor and involvement of JAK2 in differentiation of J2E erythroid cells.

S. Busfield, S. Klinken, E. Ingley, 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Disrupted Signaling in a Mutant J2E Cell Line That Shows Enhanced Viability, but Does Not Proliferate or Differentiate, with Erythropoietin (*)

D. Chappell, S. Busfield, S. Klinken, 1996, The Journal of Biological Chemistry.

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

Angel F. Lopez, H. Ramshaw, M. McCall, 2015, Haematologica.

CD123 (IL-3 Receptor α Chain) Neutralization by a Monoclonal Antibody Selectively Eliminates Human Acute Myeloid Leukemic Stem Cells.

J. Dick, Angel F. Lopez, H. Ramshaw, 2007 .

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

H. Ramshaw, L. Fabri, A. Roberts, 2014, Leukemia.

Erythropoietin induced ultrastructural alterations to J2E cells and loss of proliferative capacity with terminal differentiation.

S. Busfield, S. Klinken, G. Meyer, 1993, Growth factors.

Amiloride suppresses erythropoietin-induced proliferation and MAP kinase, but potentiates differentiation of J2E cells.

S. Busfield, S. Klinken, P. A. Tilbrook, 1995, Experimental cell research.